
Gilead and Arcus want you to believe again in TIGIT. But mixed ARC-7 data are rolling out to a tough crowd
Roche let the air out of the TIGIT party balloon with a pair of crushing Phase III failures. Now Gilead $GILD and Arcus $RCUS are back with details of their closely-watched Phase II data in Stage IV non-small cell lung cancer, hoping to spark some renewed enthusiasm for their contender and the rest of the field.
But despite some positive results in frontline therapy for patients with high PD-L1 levels, plus a claim on a potential “new standard of care,” the mid-stage readout from the ARC-7 study won’t end the running debate that has blighted expectations for the target.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.